Bausch Health's brain dysfunction treatment fails late-stage trial
Jan 23 (Reuters) - Bausch Health BHC.TO said on Friday its treatment to prevent brain dysfunction in patients with liver cirrhosis did not meet the main goal of a late-stage trial. (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Bausch Health Companies
See all newsCanada Stocks: TSX inches lower as tech and mining shares fall
Bausch Health Companies Inc. reports results for the quarter ended September 30 - Earnings Summary
Brief: Bausch Health Announces Full Redemption Of 8.500% Senior Notes Due 2027
Brief: Bausch Health Announces $50 Million Share Repurchase Program
Brief: Bausch Health Announces $50 Million Share Repurchase Program